Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA.

Janssen Biotech, Inc. has delivered on the promise of new treatments and new ways to improve the health of individuals with serious disease. Built upon a rich legacy of innovative "firsts," Janssen Biotech, Inc. pursues innovative solutions in the therapeutic areas of immunology, oncology, and nephrology. With the same unwavering passion for new challenges, They dedicate ourselves to delivering solutions for these disease states where unmet needs continue to exist.

MedImmune develops medicines for unmet medical needs worldwide. As the global biologics research and development arm of AstraZeneca, MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. Since its founding in 1988, MedImmune has remained committed to scientific innovation and medical progress, continually looking beyond standard expectations and pushing the boundaries of what is possible.

NETRIS Pharma SAS is a French company located in Lyon that develops targeted therapies for the treatment of cancer. The firm was founded in 2008 by Agnès Bernet and Patrick Mehlen. Patrick Mehlen has been the CEO since the company founding.\nThe company says this about itself: NETRIS Pharma, a clinical-stage company designs and develops anti-cancer therapeutic molecules, particularly monoclonal antibodies, to block the interaction between dependence receptors and their ligands. NETRIS Pharma, based in Lyon, is the world most advanced biopharmaceutical company targeting netrin-1.

Phylos, Inc. provides biopharmaceutical research and manufacturing services. The company is headquartered in Lexington, MA.

Shanghai Yichen Pharmaceutical Technology Co., Ltd., established on 2015-07-07, Business scope includes licensed projects:Import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:Medical Technology(genetically modified organism,Except human stem cell genetic diagnosis)Technology development in the technical field,technical consulting,Technical Services,technology transfer,laboratory reagent,Laboratory equipment and consumables,R & D and sales of instruments and meters,Research and development of pharmaceutical intermediates,Chemical Products(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals)Sales;Sales of Class I Medical Devices;Sales of Class II Medical Devices.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital (founded in 1916) and New England Deaconess Hospital (founded in 1896). Among independent teaching hospitals, Beth Israel Deaconess Medical Center consistently ranks in the top three recipients of biomedical research funding from the National Institutes of Health. Research funding totals nearly $200 million annually. BIDMC researchers run more than 850 active sponsored projects and 200 clinical trials. The Harvard-Thorndike General Clinical Research Center, the oldest clinical research laboratory in the United States, has been located on this site since 1973.

BioRestorative Therapies is a development stage company, develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments. The company focuses on the development of the ThermoStem Program that engages in the use of brown fat in connection with the cell-based treatment of Type 2 diabetes, obesity, hypertension, other metabolic disorders, and cardiac deficiencies, as well as is involved in the study of stem cells, several genes, proteins, and/or mechanisms, which are related to these diseases and disorders. It also focuses on the development of brtxDISC (Disc Implanted Stem Cells) Program for the adult stem cell treatment of disc and spine conditions, including bulging and herniated discs.

Twowin Pharma Co. Ltd. develops drugs, medical devices and cosmetic products. It offers four diagnostic kits for breast, lung, liver and prostate cancer. The company was founded in October 2009 and is headquartered in Cheongju-si, South Korea.

Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD.

Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden.

Nantong Yichen Biomedical Technology Co., Ltd., established on 2021-02-24, Business scope includes licensed projects:Technology Import and Export;Import and export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Medical Research and Experimental Development;R&D and application of cell technology;Development of Human Gene Diagnosis and Therapy Technology;Biochemical product technology research and development;Fermentation process optimization technology research and development;Engineering and Technology Research and Experimental Development;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Chemical product sales(No licensed chemical products);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Atlas Therapeutics AB, part of Alligator Bioscience AB, is a company headquartered in Stockholm, Sweden. The firm develops and manufactures antibodies drugs. On October 18, 2013 Alligator Bioscience AB acquired Atlas Therapeutics AB.